

Press release November 15<sup>th</sup> 2017

## Oncopeptides AB Interim Report July - September 2017

Stockholm, Sweden – Oncopeptides AB (Nasdaq Stockholm; ONCO) today announced the third quarter 2017 report.

*“The data from our study, O-12-M1, provides us with an increased degree of comfort regarding a positive clinical outcome in our pivotal study OCEAN”*

### SUMMARY OF Q3

#### July 1<sup>st</sup> – September 30<sup>th</sup> 2017

- Net sales amounted to 0.0 (0.0) MSEK
- Loss for the period was 51.6 (loss: 24.7) MSEK
- Loss per share, before and after dilution, was 1.30 (loss: 1.06) SEK
- On September 30<sup>th</sup> cash and cash equivalents amounted to 443.0 (5.6) MSEK

#### Significant events after the period July 1<sup>st</sup> to September 30<sup>th</sup> 2017

- On November 1<sup>st</sup>, we announced that we will present results from two clinical studies at the American Society of Hematology (ASH) annual meeting in Atlanta, USA: Final data from the phase II study called O-12-M1 and interim data from the ongoing phase II study called HORIZON. Both studies target late-stage patients with Relapsed Refractory Multiple Myeloma (RRMM).

### FINANCIAL OVERVIEW OF THE GROUP (SEK thousand):

#### Financial overview of the group (SEK thousand)

	2017 Jul - Sep	2016 Jul - Sep	2017 Jan - Sep	2016 Jan - Sep	2016 Jan - Dec
Net sales	0	-	-	-	-
Operating loss	-51,573	-24,667	-180,916	-63,394	-114,482
Loss before tax	-51,573	-24,667	-180,916	-63,394	-114,446
Loss for the period	-51,573	-24,667	-180,916	-63,394	-114,446
Earnings per share before and after dilution (SEK)	-1.30	-1.06	-4.78	-2.78	-4.88
Cash flow from operating activities	-86,158	-27,243	-225,818	-59,912	-104,262
Cash and cash equivalents at the end of the period	442,964	5,647	442,964	5,647	40,251
Research & development costs/operating expenses %	94%	82%	80%	86%	78%

## **FINANCIAL CALENDAR**

Full Year Report 2017	February 22 <sup>nd</sup> 2018
Annual General Meeting	May 17 <sup>th</sup> 2018
Interim Report Q1 2018	May 17 <sup>th</sup> 2018
Interim Report Q2 2018	July 13 <sup>th</sup> 2018

### **For further information, please contact:**

Jakob Lindberg, CEO for Oncopeptides AB  
E-mail: jakob.lindberg@oncopeptides.se  
Tel: +46 8 615 20 40

Rein Piir, Head of Investor Relations for Oncopeptides AB  
E-mail: rein.piir@oncopeptides.se  
Tel: +46 70 853 72 92

### **About Oncopeptides**

Oncopeptides is a research and development stage pharmaceutical company developing drugs for the treatment of cancer. Since the founding of the company, the focus has primarily been on the development of the lead product candidate Ygalo<sup>®</sup>, an innovative, peptidase-potentiated alkylator intended for effective and focused treatment of hematological cancers, and in particular multiple myeloma. The current clinical study program is intended to demonstrate better results from treatment with Ygalo<sup>®</sup> compared to established alternative drugs for patients with late-stage multiple myeloma. Ygalo<sup>®</sup> could potentially provide physicians with a new treatment option for patients suffering from this serious disease.

The information in the press release is information that Oncopeptides is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person above, on November 15, 2017 at 08.00 a.m. (CET).